Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

NCT03100045 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT03100045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03100045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
Lead sponsor
Johns Hopkins University
Phase
Phase 1
Overall status
Completed
Start date
April 20, 2017
Completion date
October 6, 2021
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ain2/3, alternative treatment, anal dysplasia, artesunate, hpv-related anal intraepithelial neoplasia, human papilloma virus, precancerous conditions